Binimetinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.689
CATDS
0.063
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Binimetinib. Strongest target: MEK1 at 79.1% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 79.1% | 20.9% |
| 2 | MEK2 | 43.5% | 56.5% |
| 3 | CDK9_CYCLIN_T1 | 33.3% | 66.7% |
| 4 | CAMKK2 | 23.0% | 77.0% |
| 5 | EGFR | 21.8% | 78.3% |
| 6 | ALK3_BMPR1A | 20.2% | 79.8% |
| 7 | TTBK2 | 20.0% | 80.0% |
| 8 | TGFBR2 | 19.7% | 80.3% |
| 9 | PDK2_PDHK2 | 16.9% | 83.1% |
| 10 | MUSK | 15.4% | 84.6% |
| 11 | CAMK2A | 15.4% | 84.6% |
| 12 | LYN | 15.4% | 84.6% |
| 13 | HASPIN | 14.4% | 85.6% |
| 14 | HIPK1 | 13.9% | 86.1% |
| 15 | VRK2 | 13.3% | 86.7% |
| 16 | VRK1 | 12.5% | 87.5% |
| 17 | P38A_MAPK14 | 12.3% | 87.7% |
| 18 | STK21_CIT | 12.2% | 87.8% |
| 19 | BRAF | 12.2% | 87.8% |
| 20 | PHKG1 | 11.5% | 88.5% |
Selectivity landscape
Where Binimetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Binimetinib.
Atlas insights for Binimetinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 267.22 | |
| ALLOGRAFT_REJECTION | 730.96 | |
| ANDROGEN_RESPONSE | 317.92 | |
| ANGIOGENESIS | 128.79 | |
| APICAL_JUNCTION | 871.94 | |
| APICAL_SURFACE | 84.38 | |
| APOPTOSIS | 922.88 | |
| BILE_ACID_METABOLISM | 153.42 | |
| CHOLESTEROL_HOMEOSTASIS | 197.42 | |
| COAGULATION | 59.14 | |
| COMPLEMENT | 584.80 | |
| DNA_REPAIR | 233.89 | |
| E2F_TARGETS | 831.40 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 330.21 | |
| ESTROGEN_RESPONSE_EARLY | 470.61 | |
| ESTROGEN_RESPONSE_LATE | 411.34 | |
| FATTY_ACID_METABOLISM | 58.41 | |
| G2M_CHECKPOINT | 590.79 | |
| GLYCOLYSIS | 412.65 | |
| HEDGEHOG_SIGNALING | 100.65 | |
| HEME_METABOLISM | 204.13 | |
| HYPOXIA | 541.35 | |
| IL2_STAT5_SIGNALING | 290.84 | |
| IL6_JAK_STAT3_SIGNALING | 436.50 | |
| INFLAMMATORY_RESPONSE | 547.52 | |
| INTERFERON_ALPHA_RESPONSE | 95.12 | |
| INTERFERON_GAMMA_RESPONSE | 591.78 | |
| KRAS_SIGNALING_DN | 183.00 | |
| KRAS_SIGNALING_UP | 387.09 | |
| MITOTIC_SPINDLE | 662.66 | |
| MTORC1_SIGNALING | 453.66 | |
| MYC_TARGETS_V1 | 495.40 | |
| MYC_TARGETS_V2 | 117.29 | |
| MYOGENESIS | 456.81 | |
| NOTCH_SIGNALING | 89.72 | |
| OXIDATIVE_PHOSPHORYLATION | 81.29 | |
| P53_PATHWAY | 427.23 | |
| PANCREAS_BETA_CELLS | 43.15 | |
| PEROXISOME | 126.37 | |
| PI3K_AKT_MTOR_SIGNALING | 994.61 | |
| PROTEIN_SECRETION | 263.19 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 39.64 | |
| SPERMATOGENESIS | 291.77 | |
| TGF_BETA_SIGNALING | 303.19 | |
| TNFA_SIGNALING_VIA_NFKB | 511.15 | |
| UNFOLDED_PROTEIN_RESPONSE | 184.41 | |
| UV_RESPONSE_DN | 513.00 | |
| UV_RESPONSE_UP | 525.85 | |
| WNT_BETA_CATENIN_SIGNALING | 436.15 | |
| XENOBIOTIC_METABOLISM | 202.14 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.869 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.851 |
| SRR23303752 | — | 0.838 |
| aMVAC.P_005_TURBT_S223 | — | 0.833 |
| SRR12202498 | — | 0.831 |
Annotations
Sign in to read and post annotations.
Loading…